Tag Archives: BIO Investor Forum

2012 Fall Event Preview

agenda

The 2012 BIO International Convention, the global event for biotechnology, held at the Boston Convention & Exhibition Center in Boston, Mass., wrapped this June. The event hosted a record 25,291 partnering meetings and highlighted a broad array of top-level speakers addressing critical global challenges and the top issues in biotechnology. Hosted by the Biotechnology Industry Organization (BIO), the event drew 16,505 industry leaders from 49 states and 65 countries. See what BIO President and CEO Jim Greenwood Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Opportunity or Apocalypse? Prophecies for 2012

BIF Closing Plenary

On day two of the BIO Investor Forum in San Francisco, Calif., attendees were eager to participate in the Closing Plenary. Historically, this session draws the biggest crowd of the conference and this year was no exception. Speaking to a packed audience, with standing room only, the panelists engaged in a lively discussion about the state of the industry and what is in the cards for 2012. Both Bryan Roberts, PhD, Partner, Venrock and Matthew Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

Beyond the ABCs of ADCs

Antibody

The recent FDA approval of Seattle Genetics’ antibody, Adcetris, has cast the spotlight on Antibody Drug Conjugates (ADC), leaving experts to contemplate whether this is the peak for ADCs. If history has its say though, the spotlight won’t be flickering anytime soon. Experts in this specialized antibody field discussed the latest developments and lessons of bringing ADCs through the clinic at this week’s 10th Annual BIO Investor Forum. Antibody drug conjugates hold enormous potential for treating Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Resistance is Futile – SuperDrugs for SuperBugs

800px-Acinetobacter_baumannii

“MRSA’s kill 100,000 people a year, more than AIDS,” said Mark Leuchetenberger, President and CEO, Rib-X Pharmaceuticals, Inc. With new superbugs on the rise and new superdrugs continuing to decline, the antibacterial drug discovery market is anyone’s for the taking. Attendees of the 10th Annual BIO Investor Forum participating in the Infectious Disease Therapeutic Workshop heard from an engaging panel that seemed to agree the economics of this category are driven by two things: society expects Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice

oncology

Insights in to the molecular and genetic basis of disease are driving new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions. Focusing on these new markets, a panel of industry executives and investors at the 2011 BIO Investor Forum discussed some of the most compelling Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , , , , ,